It was recently demonstrated that bacterial thymus-independent (TI) antigens confer longlasting immunity and generate memory B lymphocytes. However, reactivation of TI memory B cells is repressed in immunocompetent mice thus raising the issue of the mechanism whereby TI vaccines confer immune protection. Here, we propose an explanation to this apparent paradox by showing that a Streptococcus Pneumoniae capsular polysaccharide (PS) generates long-lived bone marrow (BM) plasma cells which frequency can be increased by CpG oligodeoxynucleotides (ODN). The adjuvant effect of CpG ODN on the PS3 Ab response is directly targeted to B cells and does not involve B-1a cells. We also demonstrated that BM plasma cells generated in response to the thymus-dependent (TD) form of the PS vaccine have a higher secretion capacity than those produced after immunization with the CpG-adjuvanted PS vaccine. Finally, we show that the PS-specific BM plasma cell compartment is sufficient to confer full protection of vaccinated mice against S. Pneumoniae infection. Altogether, our results demonstrate that TI antigens like their TD counterparts can generate both the lymphoid and the plasma cell component of B cell memory. They also provide a framework for the improvement and widespread usage of TI vaccines.
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ABSTRACT
It was recently demonstrated that bacterial thymus-independent (TI) antigens confer longlasting immunity and generate memory B lymphocytes. However, reactivation of TI memory B cells is repressed in immunocompetent mice thus raising the issue of the mechanism whereby TI vaccines confer immune protection. Here, we propose an explanation to this apparent paradox by showing that a Streptococcus Pneumoniae capsular polysaccharide (PS) generates long-lived bone marrow (BM) plasma cells which frequency can be increased by CpG oligodeoxynucleotides (ODN). The adjuvant effect of CpG ODN on the PS3 Ab response is directly targeted to B cells and does not involve B-1a cells. We also demonstrated that BM plasma cells generated in response to the thymus-dependent (TD) form of the PS vaccine have a higher secretion capacity than those produced after immunization with the CpG-adjuvanted PS vaccine. Finally, we show that the PS-specific BM plasma cell compartment is sufficient to confer full protection of vaccinated mice against S. Pneumoniae infection. Altogether, our results demonstrate that TI antigens like their TD counterparts can generate both the lymphoid and the plasma cell component of B cell memory. They also provide a framework for the improvement and widespread usage of TI vaccines. It has long been thought that generation of memory B cells is restricted to thymus-dependent (TD) responses. However the recent observation that adoptive transfer of B-1b cells from donor mice immunized with whole bacteria can confer long-lasting TI immunity to immunodeficient mice demonstrates that TI Ags generate B cell memory and that this function can be assigned to the B-1b cell subset 5 . Nonetheless the concept of TI B cell memory is at odds with the fact that, unlike TD Ags, TI Ags fail to induce a bona fide amplified recall response upon secondary immunization [6] [7] [8] [9] . This paradox was recently resolved by the demonstration that Ag-specific IgG generated during the primary response exert a negative regulatory feedback control on TI memory B cells 10 . Therefore, although B-
For personal use only. on . by guest www.bloodjournal.org From 4 1b memory cells isolated from immunized donors confer protection to immunodeficient recipients, the mechanism whereby they protect immunocompetent mice from bacterial infections is still obscure. It is now established that, in addition to memory B lymphocytes, TD Ags generate a second memory compartment constituted of long-lived BM plasma cells 11 ,12 . It is also currently admitted that accumulation of plasma cells in the BM is strictly a T cell-dependent process that requires germinal center formation 13 . In the present study, we demonstrate that TI Ags generate a BM compartment of long-lived plasma cells that is sufficient to confer full protection against infection with live bacteria. 
Immunizations.
Mice were immunized subcutaneously (s.c.) with 0. with 0.5 µg of the conjugate vaccine emulsified in alum (Pierce) followed by a boost immunization in the same conditions 28 days later.
S. pneumoniae infections.
The encapsulated serotype 3 WU2 strain of S. pneumoniae was grown in Todd-Hewitt broth supplemented with 0.5% yeast extract to mid-log phase, then enumerated by plating the suspension on blood agar plates and finally frozen as glycerol stocks at -80°C. At the time of 
Generation of chimeras.
BM Chimeras were constructed, as previously described 15 
Depletion of naive and memory B lymphocytes.
Immunized mice received total body irradiation 45 days after immunization, (750 rad, γ-ray source). Mice were reconstituted with 10 7 µMT bone marrow cells by intravenous injections.
Evaluation of the B-1 and B-2 cell depletion both in the peritoneal cavity and in the spleen was performed by flow cytometry as previously described 14 .
Statistical analysis.
Data are expressed as mean ± SEM values for individual mice. CpG1668 were co-injected (Fig. 1A) . In contrast, CpG1668 administration 1, 2 or 3 days following PS3 immunization strongly increased anti-PS3 IgM titers (Fig.1A) . Similar results were obtained after i.p. injection of PS3 and CpG1668 (data not shown). The amplitude of the adjuvant effect of CpG1668 on serum PS3 Ab titers steadily increased from day 1 to day 3 but we reproducibly found that its administration at day 2 after immunization gave the best increase in splenic ASC numbers ( Fig. 1B and C) . Similar results were obtained with several TLR agonists that target different TLRs (data not shown).
We next explored whether the adjuvant effect of CpG1668 on the PS3 Ab response was T cell-independent using CD3ε-deficient mice. The PS3 Ab response was only slightly decreased in CD3ε-deficient mice ( Fig. 1D and E), thus demonstrating that PS3 is indeed a bona-fide TI Ag. Furthermore, CpG ODN promoted a comparable enhancement of the splenic PS3 ASC numbers in WT mice (18 fold) and in T cell-deficient mice (14.5 fold) (Fig. 1D ).
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From Accordingly, the CpG-mediated enhancement of the serum anti-PS3 IgM titers was 8 fold in WT mice versus 7.5 fold in T cell-deficient mice (Fig. 1E ). Thus CpG1668 exerted a similar adjuvant effect in both T cell-competent and T cell-deficient mice, suggesting that a switch of the PS3 Ab response from a TI to a TD type cannot explain the adjuvant effect of CpG. Second, BM-chimeric mice were generated in which TLR9 was selectively invalidated in B cells (Fig. 2C ). Both groups of chimeras responded equally well to PS3 immunization, whereas a control group of mice, reconstituted with BM from μMT mice only, did not respond ( (Fig. 3A) . IgM-secreting transferred B-1a cells (Igh a ) were found in the serum of each group of recipient mice at similar levels ( Fig. 3B) , demonstrating that these transferred B-1a cells not only accumulated in the peritoneal cavity but were also functional.
The adjuvant effect of
However, PS3-specific IgM a titers were very low after immunization with PS3 alone and did not increase after injection of CpG1668. In contrast, in the same mice, CpG1668 boosted the PS3-specific IgM b response (Fig. 3C ), suggesting that B-1a cells are not involved in the PS3
Ab response or in the adjuvant effect of CpG.
Plain and adjuvanted PS3 vaccines generate a persistent pool of PS3-specific Abs and BM plasma cells.
We next studied the impact of CpG1668 on the maintenance of high PS3 Ab titers in the serum. For this purpose, mice either received a single injection of PS3 followed or not by CpG1668 injection 2 days later or were immunized with the conjugate vaccine PS3TT. This vaccine was chosen as control because it induces long-term protection not only in adults but also in children and in the elderly for whom the plain PS vaccine is inefficient 23 . Mice immunized with the PS3 vaccine elicited an IgM production that peaked at day 5, then decreased until day 60 and finally stabilized at an IgM titer slightly over 500 from day 60 onwards (Fig. 4A) . The time peak of IgM production and the kinetics of serum IgM decay were comparable in mice immunized with the CpG-adjuvanted PS3 vaccine except that the IgM titers at the plateau of the response were approximately 3 to 4 fold higher than in mice immunized with the PS3 vaccine. Serum anti-PS3 IgG followed the same decrease kinetics as IgM except for mice immunized with PS3TT in which serum IgG titers were maintained over 2700, up until 180 days post-immunization, a titer approximately 7 times higher than that obtained after immunization with the CpG1668-adjuvanted PS3 vaccine (Fig. 4B ).
Since the PS3 vaccine adjuvanted with CpG1668 allowed the maintenance of enhanced levels of anti-PS3 IgM and IgG, we next investigated whether this sustained Ab production was associated with the persistence of plasma cells in the spleen or in the BM. The highest frequency of splenic PS3-specific ASCs was found 5 days following immunization and from day 60 onwards, the IgM and IgG ASC numbers were reduced to 90 to 97% of those generated at the peak of the response, whatever the condition of immunization ( Surprisingly, in the BM, PS3-specific plasma cells start to be detected as soon as day-5 and their numbers increase until day 30 ( Fig. 4E and F) . We estimated that approximately 5 to 10% of the total plasma cells generated in the spleen at day 5 have relocated in the BM 30 days later. Furthermore, CpG1668 enhanced approximately five fold the numbers of IgG and IgM PS3-specific BM plasma cells generated in response to the PS3 vaccine ( Fig.4E and F) .
At early time points, the numbers of BM PS3-specific ASCs induced by PS3TT were lower than (IgM ASCs) or comparable to (IgG ASCs) those generated in response to the CpGadjuvanted PS3 vaccine. Unexpectedly, from day 30 to 60, these numbers slowly declined to reach a plateau that persisted up to day 180 post-immunization. By contrast, BM plasma cells generated in response to the TI form of the PS3 vaccine (adjuvanted or not by CpG1668) only slightly decreased until day 180 after immunization ( Fig. 4E and F) . Again, PS3-specific BM plasma cells generated after immunization with the plain or the CpG-adjuvanted vaccines are produced by and persist in a TI fashion (Supplementary Figure 2) .
BM plasma cells generated in response to PS3TT have a higher secretion capacity than those produced after immunization with the CpG-adjuvanted PS3 vaccine.
The number of PS3-specific ASCs detected in the BM after immunization with CpGadjuvanted PS3 vaccine exceeded that observed after PS3TT immunization while in the same time, the serum titer was similar for IgM and 10 to 15 times higher for IgG in response to PS3TT. To understand this contradiction, the secretion capacity of BM plasma cells generated by this TD or TI immunization was studied. Since the frequency of PS3-specific BM plasma cells was very low, CD138 + -enriched BM cells were seeded both in ELISPOT plates (to assess the number of PS3-specific IgM and IgG ASC) and in cell culture plates (to assess the
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level of PS3-specific IgM and IgG secretion). The secretion capacity of BM plasma cells produced in response to PS3TT was 2 fold higher for IgM and 38 fold higher for IgG than that generated in response to the CpG-adjuvanted PS3 vaccine (Fig. 5A ). This is also illustrated by the bigger size of the IgM and IgG spots obtained after immunization with PS3TT compared to PS3 and CpG (Fig. 5B) . These results suggest that TD memory plasma cells are functionally different from their TI counterparts. Fig. 6D and E) . This suggests that most of the BM plasma cells generated by the CpGadjuvanted PS3 vaccine are long-lived and that their renewal rate by PS3-specific B lymphocytes is low.
To confirm the longevity of the BM plasma cell pool generated in a TI fashion, the persistence of PS3-specific IgM were followed in naive B cell-deficient (µMT) recipient mice reconstituted with BM cells isolated from PS3-immunized mice. In order to address the possible replenishment of the transferred plasma cells pool by naive or memory B cells that may be present in the BM inoculum, control groups of mice were injected with BM cells from immunized mice that had been depleted of CD138-expressing cells. An ELISPOT performed on CD138
-BM cells showed a 90 to 95% reduction in the numbers of PS3-specific ASCs, thus confirming the efficacy of our depletion procedure (supplementary Fig. 3 ). The PS3-specific IgM titers underwent a steep decline during the first 30 days after transfer, most likely because a fraction of plasma cells transferred failed to relocalize to the BM and rapidly died (Fig. 6F ). After this initial phase of rapid decay, the PS3-specific IgM levels gradually and slowly declined to half 4 months after transfer. This means that the apparent half-life of PS3-specific serum IgM in those experimental groups is largely superior to the half-life of two days that has been described for passively transferred mouse IgM 28 . By contrast, the IgM titers in mice reconstituted with CD138-depleted BM became almost undetectable as soon as 15 days after transfer. These results suggest that the maintenance of serum PS3-specific IgM Abs in the recipients is neither due to passively transferred Abs, nor driven by restimulation of donor B cells, but rather by long-lived plasma cells.
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pneumoniae.
It has been recently described that B-1b cells provide long-lasting T cell-independent IgM memory and confer protection against Borrelia hermsii infections 5 . We thus sought to explore the contribution of long-lived PS3-specific BM plasma cells to the protection afforded by the plain and adjuvanted PS3 vaccines. All vaccinated mice were protected against a 10 6 cfu inoculum (Fig. 7A) shown to enhance the antibody response in adult and aged mice 30 .
From a mechanistic point of view, the reason why TLR agonists require to be administrated at least one day after immunization to exert their adjuvant effects remains an open question.
Because we bring evidence that CpG1668 directly targets B cells, the existence of a negative crosstalk between the TLR and the BCR signaling pathways appears as a plausible scenario.
Interestingly, the Bruton's tyrosine kinase (Btk), which is a critical component of the BCR Our data clearly establish that the delayed administration of a TLR agonist enhances the protection conferred by the PS3 vaccine, however the nature of the cells responsible for this protection was unexpected. Indeed, the pioneering study of Alugupalli et al. 5 has described that immune protection conferred by TI vaccination can be transmitted to immunodeficient mice by the transfer of lymphoid (B-1b) cells. It is now established that, in addition to memory B lymphocytes, TD Ags generate a second memory compartment constituted of long-lived BM plasma cells 11 ,12 . However, it was admitted that accumulation of plasma cells in the BM is strictly a T cell-dependent process 34 . In spite of this, expression of CXCR4, which is known to be involved in the homing of plasmablasts to the BM, is upregulated during the plasma cell differentiation process of human B cells in response to TI stimuli 35 .
Furthermore B-1 cell-derived plasma cells express high levels of Blimp-1 14, 36 , which has recently been demonstrated to play a central role in BM plasma cell survival 37 . Our present data showing that PS3 by itself elicits few but persistent plasma cells in the BM indicate that plasmablasts generated in response to TI Ags can migrate to the BM and possibly become long-lived. Moreover, the apparent differential lifespan of BM plasma cells generated in response to TI Ags and those generated in response to TD Ags, evokes the possibility that the two types of PC have either different intrinsic survival capacities or occupy different niches in the BM. At face value, the latter observation is in contradiction with the fact that the titers of serum PS3 Abs at the plateau phase remain either comparable (IgM) or higher (IgG) in mice immunized with PS3TT than in mice that were vaccinated with PS3 and CpG. However, our results point out that the Ig secretion capacity of ASCs generated by PS3TT is higher than that of ASCs produced by the polysaccharide vaccine, suggesting that plasma cells generated by TD and TI Ags are functionally different. Altogether, these results suggest that the memory plasma cell compartment is heterogeneous.
Finally, TI immunological memory appears to be more complex than expected since it In conclusion, our present work brings four major outcomes. First, we showed that a prototypic TI Ag generates a compartment of long-lived BM plasma cells. Some elements in the literature suggest that this conclusion may also apply to TI Ab response in humans. It was indeed recently described that patients treated for several months with rituximab, which 
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Conflict-of-interest disclosure: The authors declare no competing financial interests. S. pneumoniae infections. Ten-week-old mice were immunized with PS3 or PS3 followed 2 days later by injection of CpG1668 and irradiated or not 45 days later. Fifteen days after irradiation, two mice per group were checked for depletion of total B-1, B-1a, B-1b and B-2 cells in peritoneal washings as well for the frequency of the PS3-specific lymphocytes as described in Figure 6 A and B. In all irradiated groups, B cell depletion was superior to 98%
irrespective of the B cell subset considered and the frequencies of PS3-specific lymphocytes in peritoneal washings were reduced at least 100 fold as compared to control mice. Fifteen days after irradiation, the survival of non-irradiated and irradiated immune mice (8 per group) was then monitored after challenge with 10 6 (A) or 10 7 cfu (B) of live S. pneumoniae.
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